RADIUM-223 DICHLORIDE IN EXPANDED-ACCESS SETTING IN THE UNITED STATES: OVERALL AND CONCURRENT EXPERIENCE WITH ABIRATERONE OR ENZALUTAMIDE

被引：0
|
作者：
Shore, Neal
Vogelzang, Nicholas
Fernandez, Daniel
Morris, Michael
Iagaru, Andrei
Brown, Alan
Sweeney, Christopher
Smith, Matthew R.
Dicker, Adam P.
Wong, Yu-Ning
Bangerter, Keith
Gratt, Jeremy
Petrenciuc, Oana
Sartor, Oliver
机构：
来源：
JOURNAL OF UROLOGY | 2015年 / 193卷 / 04期
关键词：
D O I：
10.1016/j.juro.2015.02.1957
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP87-12
引用
收藏
页码：E1088 / E1089
页数：2
相关论文
共 26 条
  • [1] Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First US Experience from an Expanded Access Program
    Sartor, Oliver
    Vogelzang, Nicholas J.
    Sweeney, Christopher
    Fernandez, Daniel C.
    Almeida, Fabio
    Iagaru, Andrei
    Brown, Alan, Jr.
    Smith, Matthew R.
    Agrawal, Manish
    Dicker, Adam P.
    Garcia, Jorge A.
    Lutzky, Jose
    Wong, Yu-Ning
    Petrenciuc, Oana
    Gratt, Jeremy
    Shore, Neal D.
    Morris, Michael J.
    [J]. ONCOLOGIST, 2018, 23 (02): : 193 - 202
  • [2] Radium-223 (Xofigo) with concurrent abiraterone or enzalutamide: predictive biomarkers of improved overall survival in a clinically advanced cohort
    Rathbun, John Tyler
    Franklin, Gregg E.
    [J]. CURRENT PROBLEMS IN CANCER, 2019, 43 (03) : 205 - 212
  • [3] Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting.
    Sartor, A. Oliver
    Fernandez, Daniel Celestino
    Morris, Michael J.
    Iagaru, Andrei
    Brown, Alan
    Almeida, Fabio
    Sweeney, Christopher
    Smith, Matthew Raymond
    Dicker, Adam
    Wong, Yu-Ning
    Shore, Neal D.
    Gratt, Jeremy
    Petrenciuc, Oana
    Vogelzang, Nicholas J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [4] Radium-223 dichloride (Ra-223) in US expanded access program (EAP).
    Vogelzang, Nicholas J.
    Fernandez, Daniel Celestino
    Morris, Michael J.
    Iagaru, Andrei
    Brown, Alan
    Almeida, Fabio
    Sweeney, Christopher
    Smith, Matthew Raymond
    Dicker, Adam
    Wong, Yu-Ning
    Shore, Neal D.
    Bangerter, Keith
    Petrenciuc, Oana
    Sartor, A. Oliver
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [5] Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP)
    Wirth, M.
    Saad, F.
    Keizman, D.
    O'Sullivan, J. M.
    Caries, J.
    Gillessen, S.
    Karisson, Thellenberg C.
    Miller, K.
    Tucci, M.
    Paganelli, G.
    Procopio, G.
    Graft, J.
    Seger, M.
    Nilsson, S.
    Heinrich, D.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 320 - 320
  • [6] Analysis of overall survival by number of radium-223 injections received in an international expanded access program (lEAP).
    Saad, Fred
    Keizman, Daniel
    O'Sullivan, Joe M.
    Carles, Joan
    Wirth, Manfred
    Gillessen, Silke
    Thellenberg-Karlsson, Camilla
    Miller, Kurt
    Tucci, Marcello
    Paganelli, Giovanni
    Procopio, Giuseppe
    Gratt, Jeremy
    Seger, Monica
    Nilsson, Sten
    Heinrich, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP)
    Paganelli, G.
    Procopio, G.
    Cabria, M.
    Cortesi, E.
    Tucci, M.
    Farnesi, A.
    Mango, L.
    Baldari, S.
    Hamzaj, A.
    Caffo, O.
    Marchetti, P.
    Dalla Pozza, F.
    Zucali, P. A.
    Saad, F.
    Nilsson, S.
    Heinrich, D.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [8] A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Vaishampayan, U. N.
    Patel, K. R.
    Higano, C. S.
    Albany, C.
    Dawson, N. A.
    Mehlhaff, B. A.
    Quinn, D. I.
    Nordquist, L. T.
    Wagner, V. J.
    Shen, J.
    Trandafir, L.
    Sartor, O.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 340 - 341
  • [9] Exploring the effects of abiraterone/enzalutamide failure prior to the initiation of radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.
    Cotogno, Patrick
    Ledet, Elisa M.
    Steinberger, Allie E.
    Chowdry, Rajasree Pia
    Stolten, Michael
    Sartor, Oliver
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [10] Radium-223 (Ra-223) in sequence or in concurrent use with abiraterone acetate (AA) or enzalutamide (E) in metastatic castration resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP)
    Zastrow, S.
    Saad, F.
    Heinrich, D.
    Gillessen, S.
    OSullivan, J.
    Carles, J.
    Miller, K.
    Huang, L.
    Van Tol, Seeger M.
    Nilsson, S.
    Heidenreich, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 94 - 94
123